Funded Project Details - FY2021
|Title:|| Nanomicellar antiviral strategies for RSV infection|
Shyam S. Mohapatra
|Congressional District Code:
||Biomedical Laboratory R&D
|| July 2017 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
The major goal of this program is to further develop and translate recent discoveries in biology of respiratory syncytial virus (RSV), an important pathogen that infects an estimated 64 million people and causes ~200, 000 deaths globally every year. In the US, RSV causes >11,000 deaths of elderly annually. There is no effective treatment or vaccine against RSV infection. Currently, only high-risk infants receive antibody-based prophylaxis, which is expensive and moderately effective in reducing...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.